The drug was tested against placebo and showed approximately 89% effectiveness in preventing hospitalizations or deaths compared with placebo, based on preliminary results in around 1,200 people. No one in the test who received Pfizer treatment died compared to the 12 deaths among placebo recipients. Pfizer chief executive Mikael Dolsten said he was awaiting approval from high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon.
Pfizer will already allow generic manufacturers to begin shipping versions of the drug to 95 low- and middle-income countries through a licensing agreement with the international public health group Medicines Patent Pool. (MPP).
Performance of 5 years for Pfizer Inc. (Source: Investing.com)